A password is required to submit a request for an internal transfer. In order to obtain the password you can check any of the following resources: Login to the employee portal, check the current issue of "Regional High Points" newsletter, contact HR, or read this week's "Daily Announcements".
Immunoglobulins are special proteins in the blood that fight infections. Some of our white blood cells make them. They are also known as antibodies. Antibodies are important for the immune system. In immunoglobulin therapy (IVIg), extra immunoglobulins from a donor are injected into your blood.
The site where the IV was put in may become irritated. You should check with your doctor if this happens.
You may begin to see an improvement in your original symptoms as soon as 24-48 hours following the procedure. For some, it may be 3-4 weeks before an improvement is seen.
Immunoglobulin therapy is usually done in cycles. For an infection or other immune system deficiency, therapy is usually recommended every 3-4 weeks. If you have a neurological or autoimmune disease, therapy is administered for five days a month for 3-6 months. Following the initial therapy, maintenance therapy is administered every 3-4 weeks.
As with the introduction of any foreign substance or chemical to the body, the possibility of allergic reaction exists. If you experience any of the following symptoms of anaphylactic shock (severe allergic reaction), you should call the doctor immediately:
Wheezing and/or difficulty breathing
Slurred or abnormal speech
Rapid heartbeat or heart palpitations, weak or rapid pulse
Adverse effects of intravenous immunoglobulin therapy. American Academy of Allergy Asthma & Immunology website. Available at: ...(Click grey area to select URL) mc/currentliterature/selectedarticles/2003archive/intravenous_immunoglobulin.html.
Accessed May 27, 2007.
Darabi, K, Abdel-Wahab, O, et al. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
Emerson GG, Herndon CN, et al.
Nydegger UE. Safety and side effects of IV immunoglobulin therapy.
Clin Exp Rheum. 1996;14(suppl 15):S53-57.
Orange, JS, Hossny, EM, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
J Allergy Clin Immunol.
Sherer Y, Levy Y, et al. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 2000;39:421-426. Available at ...(Click grey area to select URL) Accessed May 28, 2007.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.